| ǥ :
|
ȣ - 500660 310 |
| Multiple antiplatelet therapy after drug-eluting stent implantation
: How long and How many?
; Prospective, randomized, multicenter trial |
| 가톨릭대학교 의과대학 순환기 내과학 교실 |
| 박찬석, 전두수, 길욱현, 임민경, 최민석, 박춘준, 김성훈, 최윤석, 김동빈, 장성원, 신동일, 허성호, 김지훈, 박철수, 김범준, 이종민, 장기육, 김희열, 유기동, 정욱성, 승기배, 김재형, 최규보, 홍순조 |
Background The patients underwent DES implantation should take antiplatelet drugs.There is no definite recommendation for adequate combination and duration of the antiplatelet drugs. Methods and results Since May 2005, we recruited the patients at 8 hospitals of Catholic university medical college. The patients were divided into two groups. (Protocol-1, SES in simple lesion; Protocol-2, SES in complex lesion and PES in all coronary lesion) The primary end point was death, MI and stent thrombosis. The secondary end point was TVR or TLR and side effects of drugs including major bleeding, stroke and hepatic dysfunction. Total 1035 patients were enrolled until July 2006. Mean duration of follow up was 5.9 months. 578 patients followed more than 6 months were subjected to analyze. Conclusion There were no differences of outcomes between the groups. It should be notified that there was only one death due to sepsis in protocol 1-3. We planned to recruit more pateint for further analysis,
|
|
1-1 |
Aspirin /clopidogrel continuously |
|
1-2 |
Aspirin /Clopidogrel for 3 months
|
Then, Aspirin/ cilostazol
continuously |
|
1-3 |
Aspirin /Clopidogrel for 3
months |
Then, only Aspirin
continuously |
|
2-1 |
Aspirin /Clopidogrel /cilostazol for
6 months |
Then, Aspirin/ clopidogrel
continuously |
|
2-2 |
Aspirin/ clopidogrel
continuously |
|
2-3 |
Aspirin/ Clopidogrel/ cilostazol for
6 months |
Then, Aspirin/ cilostazol
continuously |
|
2-4 |
Aspirin/Clopidogrel for 6
months |
Then, Aspirin/ cilostazol
|
|
|
Primary end point |
Secondary end point |
|
1-1 (n=73) |
sudden cardiac death (n=1) |
TLR (n=1), TVR (n=1) |
|
1-2 (n=38) |
|
CVA (n=1), TLR (n=1), TVR (n=2) |
|
1-3 (n=39) |
death (n=1) |
TLR (n=1) |
|
2-1 (n=108) |
subacute thrombosis (n=1) |
TLR (n=3) |
|
2-2 (n=119) |
subacute thrombosis (n=1) |
TLR (n=5), TVR (n=2) |
|
2-3 (n=93) |
Death due to in-stent thrombosis
(n=1) |
CVA (n=1), Bleeding (n=2), TLR (n=7), TVR
(n=1) |
|
2-4 (n=108) |
sudden cardiac arrest (n=1) |
CVA (n=1), TLR (n=1), hepatic dysfunction
(n=1) |
|
|
|
